Construction and characterization of an anti-CD20 mAb nanocomb with exceptionally excellent lymphoma-suppressing activity

References

• ChesonBDLeonardJPMonoclonal antibody therapy for B-cell non-Hodgkin’s lymphomaN Engl J Med2008359661362618687642
   PubMed Web of Science ®Google Scholar
• ShanklandKRArmitageJOHancockBWNon-Hodgkin lymphomaLancet2012380984484885722835603
   PubMed Web of Science ®Google Scholar
• LimSHLevyRTranslational medicine in action: anti-CD20 therapy in lymphomaJ Immunol201419341519152425086174
   PubMed Web of Science ®Google Scholar
• FisherRIGaynorERDahlbergSComparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphomaN Engl J Med199332814100210067680764
   PubMed Web of Science ®Google Scholar
• NarayanVAMohwinckelMPisanoGYangMManjiHKBeyond magic bullets: true innovation in health careNat Rev Drug Discov2013122858623370233
   PubMed Web of Science ®Google Scholar
• RietherCSchürchCOchsenbeinAFFrom “magic bullets” to specific cancer immunotherapySwiss Med Wkly2013143w1373423348718
   PubMed Web of Science ®Google Scholar
• ChaoMPAlizadehAATangCAnti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphomaCell2010142569971320813259
   PubMed Web of Science ®Google Scholar
• TaylorRPLindorferMAZentCSAnti-CD20 antibody therapy for B-cell lymphomasN Engl J Med20123679876877 author reply 87822931338
   PubMedGoogle Scholar
• TedderTFStreuliMSchlossmanSFSaitoHIsolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytesProc Natl Acad Sci U S A19888512082122448768
   PubMed Web of Science ®Google Scholar
• AndersonKCBatesMPSlaughenhouptBLPinkusGSSchlossmanSFNadlerLMExpression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiationBlood1984636142414336609729
   PubMed Web of Science ®Google Scholar
• GuptaPGoldenbergDMRossiEADual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomasBlood2012119163767377822271448
   PubMed Web of Science ®Google Scholar
• PressOWAppelbaumFLedbetterJAMonoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomasBlood19876925845913492224
   PubMed Web of Science ®Google Scholar
• DavisTAGrillo-LópezAJWhiteCARituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin’s lymphoma: safety and efficacy of re-treatmentJ Clin Oncol200018173135314310963642
   PubMed Web of Science ®Google Scholar
• UjjaniCChesonBDThe current status and future impact of targeted therapies in non-Hodgkin lymphomaExpert Rev Hematol201362191202 quiz 20323547867
   PubMed Web of Science ®Google Scholar
• ZhaoLTongQQianWEradication of non-Hodgkin lymphoma through the induction of tumor-specific T-cell immunity by CD20-Flex BiFPBlood2013122264230423624178967
   PubMed Web of Science ®Google Scholar
• RezvaniARMaloneyDGRituximab resistanceBest Pract Res Clin Haematol201124220321621658619
   PubMed Web of Science ®Google Scholar
• TaylorRPLindorferMAImmunotherapeutic mechanisms of anti-CD20 monoclonal antibodiesCurr Opin Immunol200820444444918585457
   PubMed Web of Science ®Google Scholar
• KlepfishASchattnerAGhotiHRachmilewitzEAAddition of fresh frozen plasma as a source of complement to rituximab in advanced chronic lymphocytic leukaemiaLancet Oncol20078436136217395110
   PubMed Web of Science ®Google Scholar
• BhatRWatzlCSerial killing of tumor cells by human natural killer cells – enhancement by therapeutic antibodiesPLoS One200723e32617389917
   PubMed Web of Science ®Google Scholar
• AlduaijWIvanovAHoneychurchJNovel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignanciesBlood2011117174519452921378274
   PubMed Web of Science ®Google Scholar
• HertingFFriessTBaderSEnhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphomaLeuk Lymphoma20145592151516024304419
   PubMed Web of Science ®Google Scholar
• TrinhKRVasuthasawatAStewardKKYamadaRETimmermanJMMorrisonSLAnti-CD20-interferon-β fusion protein therapy of murine B-cell lymphomasJ Immunother201336530531823719241
   PubMed Web of Science ®Google Scholar
• BeersSAChanCHJamesSType II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activationBlood2008112104170417718583569
   PubMed Web of Science ®Google Scholar
• MössnerEBrünkerPMoserSIncreasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicityBlood2010115224393440220194898
   PubMed Web of Science ®Google Scholar
• ZhaoLXieFTongXCombating non-Hodgkin lymphoma by targeting both CD20 and HLA-DR through CD20-243 CrossMabMAbs20146374074824670986
   PubMed Web of Science ®Google Scholar
• CraggMSWalsheCAIvanovAOGlennieMJThe biology of CD20 and its potential as a target for mAb therapyCurr Dir Autoimmun2005814017415564720
   PubMedGoogle Scholar
• GlennieMJFrenchRRCraggMSTaylorRPMechanisms of killing by anti-CD20 monoclonal antibodiesMol Immunol200744163823383717768100
   PubMed Web of Science ®Google Scholar
• RileyJKSliwkowskiMXCD20: a gene in search of a functionSemin Oncol2000276 Suppl 12172411225995
   PubMed Web of Science ®Google Scholar
• HofmeisterJKCooneyDCoggeshallKMClustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosisBlood Cells Mol Dis200026213314310753604
   PubMed Web of Science ®Google Scholar
• IvanovABeersSAWalsheCAMonoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cellsJ Clin Invest200911982143215919620786
   PubMed Web of Science ®Google Scholar
• GrønbaekKJäätteläMEngaging the lysosomal compartment to combat B cell malignanciesJ Clin Invest200911982133213619620776
   PubMed Web of Science ®Google Scholar
• JakMvan BochoveGGvan LierRAElderingEvan OersMHCD40 stimulation sensitizes CLL cells to rituximab-induced cell deathLeukemia201125696897821403646
   PubMed Web of Science ®Google Scholar
• YangXZhangXFuMLTargeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responsesCancer Cell2014251374824434209
   PubMed Web of Science ®Google Scholar
• MarkmanJLRekechenetskiyAHollerELjubimovaJYNanomedicine therapeutic approaches to overcome cancer drug resistanceAdv Drug Deliv Rev20136513–141866187924120656
   PubMed Web of Science ®Google Scholar
• SeymourLWPassive tumor targeting of soluble macromolecules and drug conjugatesCrit Rev Ther Drug Carrier Syst1992921351871386002
   PubMed Web of Science ®Google Scholar
• MaedaHMacromolecular therapeutics in cancer treatment: the EPR effect and beyondJ Control Release2012164213814422595146
   PubMed Web of Science ®Google Scholar
• IyerAKKhaledGFangJMaedaHExploiting the enhanced permeability and retention effect for tumor targetingDrug Discov Today20061117–1881281816935749
   PubMed Web of Science ®Google Scholar
• LiWZhaoHQianWChemotherapy for gastric cancer by finely tailoring anti-Her2 anchored dual targeting immunomicellesBiomaterials201233215349536222542611
   PubMed Web of Science ®Google Scholar
• WuKYangJLiuJKopečekJCoiled-coil based drug-free macromolecular therapeutics: in vivo efficacyJ Control Release2012157112613121843563
   PubMed Web of Science ®Google Scholar
• WuKLiuJJohnsonRNYangJKopecekJDrug-free macromolecular therapeutics: induction of apoptosis by coiled-coil-mediated cross-linking of antigens on the cell surfaceAngew Chem Int Ed Engl20104981451145520101660
   PubMed Web of Science ®Google Scholar
• ChuTWYangJKopečekJAnti-CD20 multivalent HPMA copolymer-Fab’ conjugates for the direct induction of apoptosisBiomaterials201233297174718122795544
   PubMed Web of Science ®Google Scholar
• AluriSRShiPGustafsonJAA hybrid protein-polymer nanoworm potentiates apoptosis better than a monoclonal antibodyACS Nano2014832064207624484356
   PubMed Web of Science ®Google Scholar
• HuwylerJWuDPardridgeWMBrain drug delivery of small molecules using immunoliposomesProc Natl Acad Sci U S A1996932414164141698943078
   PubMed Web of Science ®Google Scholar
• MacKayJAChenMMcDanielJRLiuWSimnickAJChilkotiASelf-assembling chimeric polypeptide-doxorubicin conjugate nanoparticles that abolish tumours after a single injectionNat Mater200981299399919898461
   PubMed Web of Science ®Google Scholar
• GiacomelliCLe MenLBorsaliRPhosphorylcholine-based pH-responsive diblock copolymer micelles as drug delivery vehicles: light scattering, electron microscopy, and fluorescence experimentsBiomacromolecules20067381782816529419
   PubMed Web of Science ®Google Scholar
• YoshimuraTEsumiKPhysicochemical properties of anionic triple-chain surfactants in alkaline solutionsJ Colloid Interface Sci2004276245045515271573
   PubMed Web of Science ®Google Scholar
• LiBZhaoLGuoHCharacterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphomaBlood2009114245007501519828699
   PubMed Web of Science ®Google Scholar
• RegazziMBIaconaIAvanziniMAPharmacokinetic behavior of rituximab: a study of different schedules of administration for heterogeneous clinical settingsTher Drug Monit200527678579216306856
   PubMed Web of Science ®Google Scholar
• DaydéDTernantDOhresserMTumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20Blood2009113163765377219029438
   PubMed Web of Science ®Google Scholar
• ZhangYHuoMZhouJXieSPKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft ExcelComput Methods Programs Biomed201099330631420176408
   PubMed Web of Science ®Google Scholar
• HanahanDWeinbergRAHallmarks of cancer: the next generationCell2011144564667421376230
   PubMed Web of Science ®Google Scholar
• HanahanDWeinbergRAThe hallmarks of cancerCell20001001577010647931
   PubMed Web of Science ®Google Scholar
• WuCYingHGrinnellCSimultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulinNat Biotechnol200725111290129717934452
   PubMed Web of Science ®Google Scholar
• FuQCashSEAndersenJJCD43 in the nucleus and cytoplasm of lung cancer is a potential therapeutic targetInt J Cancer201313281761177023015282
   PubMed Web of Science ®Google Scholar
• VelentzasADNezisIPStravopodisDJPapassideriISMargaritisLHMechanisms of programmed cell death during oogenesis in Drosophila virilisCell Tissue Res2007327239941417004067
   PubMed Web of Science ®Google Scholar